F S&P 500
4,999.75 -49.25 (-0.98%) F Dow Jones
37,674.00 -333.00 (-0.88%) F Nasdaq
17,333.75 -213.50 (-1.22%) E-mini Russell 2000 Index Futur
1,935.90 -22.20 (-1.13%) Petróleo
85.03 +2.30 (+2.78%) Oro
2,401.10 +3.10 (+0.13%)
Novartis AG (NOVN.SW)
Novartis AG
Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com
Sector(es): Healthcare
Industria: Drug Manufacturers - General
Empleados a tiempo completo: 76,057
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Vasant Narasimhan M.D. | Chief Executive Officer | 7.33M | N/D | 1976 |
| Mr. Harry Kirsch | Chief Financial Officer | 3.65M | N/D | 1965 |
| Mr. Victor Bulto | President of US | 3M | N/D | 1978 |
| Dr. Patrick Horber M.D. | President of International | 6.68M | N/D | 1970 |
| Dr. Steffen Lang Ph.D. | President of Operations | 2.14M | N/D | 1967 |
| Paul Penepent | Head of Group Financial Reporting and Accounting | N/D | N/D | N/D |
| Dr. Samir Shah M.D. | Global Head of Investor Relations | N/D | N/D | 1962 |
| Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer | 1.42M | N/D | 1968 |
| Ms. Karen L. Hale | Chief Legal Officer | 2.14M | N/D | 1968 |
| Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 1.92M | N/D | 1968 |
Descripción
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Gestión corporativa
La calificación ISS Governance QuickScore de Novartis AG a partir del 1 de abril de 2024 es 1. Las puntuaciones principales son Auditoría: 1; Junta: 2; Derechos del accionista: 1; Compensación: 3.
